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ABSTRACT
Sodium-glucose cotransporter 2 (SGLT2)
inhibitors are a novel class of drugs that have
been extensively investigated for the treatment
of hyperglycemia in type 2 diabetes mellitus
(T2DM). These drugs reduce hyperglycemia by
blocking renal glucose reabsorption, thereby
promoting increased renal glucose excretion.
Beyond glycemic control, these drugs have
other beneficial effects on cardiovascular (CV)
risk factors. The present review discusses the
potential role of SGLT2 inhibitors in treating
CV complications (acute and chronic)
associated with T2DM.
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INTRODUCTION
Cardiovascular disease (CVD) and type 2
diabetes mellitus (T2DM) have reached
epidemic proportions worldwide, becoming
increasingly pressing public health problems.
The prevalence of T2DM ranges from 6.9% to
10.2% in developed countries, and exceeds 7%
in developing countries [1, 2]. CVD accounts for
17.5 million deaths annually, an estimated 31%
of all deaths worldwide [3].
A growing body of evidence suggests strong
links between T2DM, CVD and hypertension
[high blood pressure (BP)]. Firstly, T2DM is
known to be a major risk factor for
cardiovascular (CV) morbidity and mortality
[4]. In addition to microvascular complications
(nephropathy, retinopathy and neuropathy),
T2DM is associated with macrovascular
complications including CVD, cerebrovascular
disease and peripheral artery disease. Secondly,
the majority of patients with T2DM are
overweight or obese, a further risk factor for
both CVD and hypertension [5].
Finally, hypertension is a common
co-morbidity in both CVD and T2DM. A
substantial proportion of people with T2DM
have concomitant hypertension (20–60%,
Enhanced content To view enhanced content for this
article go to http://www.medengine.com/Redeem/
CBE4F06021C48730.
S. Kalra (&)
Department of Endocrinology, Bharti Hospital,
Karnal, Haryana, India
e-mail: brideknl@gmail.com
Cardiol Ther (2016) 5:161–168
DOI 10.1007/s40119-016-0069-z
depending on age, sex, ethnicity and body mass
index). Hypertension almost doubles the risk of
all-cause mortality, and increases the risk of
coronary artery disease threefold [6, 7]. In
addition, hypertension enhances the
progression of diabetic complications such as
nephropathy, retinopathy and neuropathy.
Lowering of BP, using appropriate
antihypertensive treatment, reduces the risk of
complications in T2DM patients [8–10]. The 8th
Joint National Committee (JNC)
recommendations for the management of
hypertension in adults suggest targets of
\140 mmHg for systolic BP (SBP) and
\85–90 mmHg for diastolic BP (DBP) in
patients with T2DM [11]. However,
hypertension associated with T2DM is
especially challenging to treat [12], with most
T2DM patients needing more than one drug for
BP control. A systematic survey of general
practitioners in Canada revealed that 28–39%
of hypertensive patients with underlying T2DM
failed to achieve the BP targets recommended
by the current JNC guidelines [13, 14]. New and
improved treatment options for BP lowering are
urgently needed to improve CV prognosis
among patients with T2DM and hypertension.
Sodium-glucose cotransporter 2 (SGLT2)
inhibitors are a novel class of drugs that have
been extensively investigated for the treatment
of hyperglycemia in T2DM. These drugs reduce
hyperglycemia by blocking renal glucose
reabsorption, thereby promoting increased
renal excretion of glucose [15]. Over and
above glycemic control, these drugs have
shown benefit with respect to a number of CV
risk factors [16, 17]. The present review
discusses the potential role of SGLT2 inhibitors
in addressing risk factors and complications
associated with T2DM, such as hypertension,
from a cardiology perspective. It also discusses
the potential use of SGLT2 in acute and chronic
CV syndromes and obesity.
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
SGLT2 INHIBITORS
The United States Food and Drug
Administration and the European Medicines
Agency have approved 3 drugs in this class:
canagliflozin, dapagliflozinand empagliflozin. A
number of other members of this class are in
clinical development. A large meta-analysis of
data from 58 trials of SGLT2 inhibitors
(dapagliflozin or canagliflozin) concluded that
SGLT2 inhibitors have a statistically significant
favorable effect on HbA1c [17]. This effect was
consistently observed in T2DM patients on
background treatment with a range of
antihyperglycemic agents, including glipizide
and insulin [18]. Similar beneficial effects were
reported with empagliflozin; in patients who
were uncontrolled with metformin, the
placebo-adjusted mean decrease in HbA1c was
0.57% with 10 mg empagliflozin and 0.64%
with 25 mg after 24 weeks of treatment [19].
The available safety data indicate that SGLT2
inhibitors are generally well tolerated [20, 21].
Hypoglycemia is less common than with many
other classes of antihyperglycemic agents, since
the mechanism of action is independent of
insulin. Urinary tract infections and genital
infections (mainly fungal) are more commonly
reported, but these are generally mild in nature
and can be easily treated [22, 23]. Volume
depletion, another common side effect
reported with SGLT2 inhibitors, can occur as a
result of the osmotic diuresis associated with
SGLT2 inhibitor-induced glycosuria. Other side
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effects/symptoms are frequent urination, thirst
and, potentially, orthostatic hypotension [20].
However, these are not clinically significant,
and rarely lead to discontinuation of therapy.
EFFECTS ON HEMODYNAMICS
The favorable effects of SGLT2 inhibitors on a
number of conventional CV risk factors, such as
BP, blood glucose levels and body weight, are
well documented (Fig. 1). Clinical studies are
under way to investigate other effects of these
drugs on other CV risk factors and outcomes
[24].
In particular, the osmotic diuresis effects of
SGLT2 inhibitors have received considerable
attention. Along with blocking glucose
reabsorption, SGLT2 inhibitors also reduce
protein and sodium reabsorption in the
nephron, resulting in a mild osmotic diuresis
[25]. The loss of volume and sodium activates
the renin-angiotensin-aldosterone (RAAS)
system and initiates a counter-regulatory
compensatory mechanism by the kidneys to
maintain sodium homeostasis [26] (Fig. 1). In
addition, weight loss resulting from glycosuria
and the associated net caloric loss may further
contribute to BP lowering.
Preload Reduction
Because of their intriguing effects on renal
hemodynamics, it has been suggested that
SGLT2 inhibitors could have a role in treating
T2DM patients with both types of chronic heart
failure (HF), namely reduced ejection fraction
HF (HFrEF) or preserved ejection fraction HF
(HFpEF). HFrEF is characterized by a left
ventricular ejection fraction of B50%,
increased left ventricular mass, as well as
increased end-diastolic and end-systolic
volume. This is typically seen in diabetic
cardiomyopathy, valval heart diseases and
cardiomyopathy. In contrast, HFpEF is
characterized by a left ventricular ejection
fraction of [50%, increased left ventricular
mass, unchanged or decreased end-diastolic
and end-systolic volume. This type of HF is
seen in restrictive cardiomyopathy,
hypertensive heart disease, and hypertrophic
obstructive cardiomyopathy. SGLT2
inhibitor-induced diuresis would be expected
to result in preload reduction (Fig. 1), which
may be beneficial in chronic HF patients with a
reduced ejection fraction. However, care should
be taken when using diuretics in such patients,
due to the possibility of excessive preload
reduction [27].
Afterload Reduction
There is evidence that SGLT2 inhibitors may
reduce afterload as well as preload. Cherney
et al. studied hemodynamic changes in type 1
diabetes mellitus patients who were treated
Fig. 1 Various Pharmacological actions of SGLT2 inhibi-
tors. RAAS renin aldosterone angiotensin system, SGLT2
sodium-glucose cotransporter 2
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with empagliflozin 25 mg daily for 8 weeks. This
study documented reductions in BP, arterial
stiffness and sympathetic nervous system
activity. Radial artery and carotid waveforms,
augmentation index (AIx), heart rate, and aortic
pulse wave velocity were measured. The AIx is
an indicator of central aortic pressure
enhancement by a reflected pulse wave and is
used as a predictor of adverse CV events. AIx is a
ratio calculated using BP waveforms; the greater
the augmentation or enhancement, the greater
the degree of arterial stiffness. After 8 weeks of
treatment, AIx was significantly reduced in the
empagliflozin group, compared with the
placebo group, suggesting reductions in the
afterload as well as the preload (Fig. 1). No
significant changes in sympathetic nervous
system activity were reported [28], further
suggesting that SGLT2 inhibitors reduce
afterload.
SGLT2 inhibitors have also been reported to
reduce the levels of plasma uric acid. This is
thought to be due to their effects on a urate
transporter, solute carrier family 2, facilitated
glucose transporter member 9, which transports
urate into the urine in exchange for glucose
[18].
Effects on BP
Almost all SGLT2 inhibitor studies have
reported significant BP reductions, with a
larger effect on SBP (1.66–6.90 mmHg) than on
DBP (0.88–6.99 mmHg) (Fig. 1). A pooled
analysis of 4 Phase III, placebo-controlled
clinical studies indicated modest reductions in
SBP with canagliflozin (-3.3 and -4.5 mmHg
with the 100 and 300 mg doses, respectively)
[29]. Similarly, analysis of pooled data from 4
Phase III empagliflozin clinical trials revealed
significant placebo-adjusted reductions in SBP
with empagliflozin treatment (10 or 25 mg once
daily for 24 weeks as a monotherapy or add-on
therapy to metformin, metformin plus
sulfonylurea, or pioglitazone with or without
metformin) [30]. There are reports that
dapagliflozin had effects on reducing the BP.
In a study, which compared dapagliflozin as
monotherapy in various dosing schedule vs.
placebo in T2DM patients, reported reduction
in office SBP and DBP in those patients up to
-5.7 and 3.3 mmHg, respectively. Few studies
had explored the efficacy of this drug as an
add-on to the oral antidiabetics. In a study
consisting of over 800 patients with T2DM who
were on stable insulin dose with or without
other oral antidiabetics, on add on
dapagloflozin or placebo, the researchers
reported reductions in SBP with dapagliflozin
(mean change: -1.49 mmHg in the placebo
group vs -5.30, -4.33, and -4.09 mmHg in the
groups receiving 2.5, 5, and 10 mg of
dapagliflozin, respectively) and non-significant
DBP reductions (-1.31 with placebo vs -2.96,
-2.64, and -2.85 mmHg in the groups who
received 2.5, 5, and 10 mg of dapagliflozin).
Effect on Pulse
There is no increase in pulse rate with SGLT2
inhibitors. A 104-week outcome study of
canagliflozin indicated that the 100 and
300 mg dose reduced SBP and DBP compared
with glimepiride, with no notable changes in
pulse rate [31]. This contrasts with the
tachycardic reported with use of other glucose
lowering drugs such as glucagon like peptide 1
receptor agonists.
In the short term, these BP-lowering effects
have been attributed to both preload and
afterload reduction. This is a unique feature of
SGLT2 inhibitors, which needs to be
highlighted in cardiology circles. Long-term
effects may be mediated through RAAS
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activation and/or reductions in body weight
[26].
EFFECTS ON BODY WEIGHT
Reductions in body weight are consistently
observed with SGLT2 inhibitor treatment
(Fig. 1). This effect may be attributed to
diuresis or volume depletion, as well as to net
loss of calories in the form of glucose. Among
T2DM patients inadequately controlled with
metformin, weight loss occurred with
dapagliflozin treatment, compared with weight
gain on glipizide (-3.2 vs. ?1.4 kg over
52 weeks of treatment, dapagliflozin vs.
glipizide; P\0.0001) [31]. Similar observations
have been made regarding canagliflozin
treatment. In T2DM patients inadequately
controlled with metformin and sulfonylureas,
reductions of -1.9 and -2.5 kg were achieved
with 100 and 300 mg canagliflozin, vs. -0.8 kg
with placebo [30, 32]. Weight loss with SGLT2
inhibitors was also documented in patients who
were taking a combination of oral antidiabetic
drugs and insulin (P\0.001). The sustained
impact on body weight is thought to be the
result of fat loss.
EFFECTS ON LIPID PROFILES
A small number of studies have reported
beneficial effects of SGLT2 inhibitors on lipid
parameters, including reductions in triglyceride
levels and small increases in high-density
lipoprotein cholesterol (HDL-C) levels
[14, 33, 34] (Fig. 1). Increases in total
cholesterol and low-density lipoprotein
cholesterol levels have also been reported. A
study of T2DM patients who were uncontrolled
with metformin ([1500 mg/day) reported an
increase in HDL-C and a reduction in
triglycerides with dapagliflozin compared with
placebo [18]. However, the clinical significance
of these changes in lipid parameters is not yet
known.
EFFECTS ON CV OUTCOMES
Although SGLT2 inhibitor treatment appears to
improve a number of classical CV risk factors
such as BP, body weight and HbA1c in the short
term, the long-term benefits (e.g. sustained
reductions in risk factors) have yet to be
ascertained. To date, only a handful of studies
have reported CV outcomes, as these were
generally not planned as primary outcomes in
the pivotal SGLT2 inhibitor trials [33].
In the absence of long-term real-world data,
a modeling study by Dziuba et al. [35]
investigated the effects of adding dapagliflozin
to standard therapy in a simulated T2DM
population. Based on modeling, a greater
decrease in CV and microvascular
complications was predicted for dapagliflozin
added to standard therapy, compared with
standard therapy alone [35].
Subsequently, the effects of empagliflozin on
CV outcomes were investigated in a large
multi-country study of over 7000 T2DM patients
with established CVD [36]. This study was a
randomized, double-blind, placebo-controlled
trial to investigate the effects of empagliflozin
(10or25 mgadded to standardcare) onCVevents
inpatientswithT2DMwhowereathighriskofCV
events. The primary outcome was a composite of
death from CV causes, nonfatal myocardial
infarction (excluding silent myocardial
infarction), or nonfatal stroke; the key secondary
outcomewas a composite of theprimaryoutcome
plus hospitalization for unstable angina.
High-risk T2DM patients who received
empagliflozin plus standard care had
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significantly lower rates of the primary composite
outcome and of death from any cause than the
placebo group (standard care only) [35].
The Canagliflozin Cardiovascular Assessment
Study (CANVAS) trial (ClinicalTrials.gov
identifier: NCT01032629) is among several
ongoing trials for which interim analysis results
have been published. In this analysis, 201
4-point major adverse cardiac events (MACE)
occurred in over 9000 patients with a hazard
ration of 1.0 (95% CI: 0.72, 1.39).This study will
continue until 420 3-point events have been
accrued, and will be evaluated for the potential
CV benefits. This study started in 2009 and is
expected to conclude the final results in 2017.
One of the largest ongoing trials,
DECLARE-TIMI58 (Dapagliflozin Effect on
CardiovascuLAR Events) (ClinicalTrials.gov
identifier: NCT01730534) is a multi- national
randomized, double blind, placebo controlled
Phase IIIB superiority trial designed to test the
hypothesis that patients with T2DM, who were
on long term dapaglifolzin, will have a reduced
incidence of the composite endpoint of CV
death, myocardial infarction or ischemic stroke.
This study will also seek to exclude the
unacceptable CV risk from the drug in these
patients. The teams have plans to enroll over
17,000 participants with T2DM and have
indicated a target of 1390 3-point MACE. The
results are expected to be out in 2018, with a
hope to see if dapagliflozin could offer CV
benefits as well as addressing safety related issues.
In a recently published study of the
EMPA-REG OUTCOME trial (ClinicalTrials.gov
identifier: NCT01131676), it was found that in
patients with T2DM who were at high CV risk,
empagliflozin was effective in slowing the
progression of kidney disease. With an aim to
assess the long term renal effects of
empagliflozin, a secondary analysis of the
pre-specified component of the secondary
microvascular outcome of the trial was
performed. The study reported a lower
incidence or worsening nephropathy in the
Empagliflozin arm (12.7%) when compared
with the placebo (18.8%). There were raised
serum creatinine levels in 1.5% of patients in
the empagliflozin group versus 2.6% in the
placebo group, which was a significant
reduction of the relative risk. The need for
renal replacement therapy was lower in the
empagliflozin group than the placebo. The
study concluded that the use of empagliflozin
in patients with T2DM at high CV risk was
associated with slower progression of kidney
disease compared with the placebo [37].
CONCLUSION
The safety and efficacy of SGLT2 inhibitors
(including canagliflozin, dapagliflozin and
empagliflozin) for the treatment of
hyperglycemia in T2DM has been well
documented. For now, these drugs have proven
to be a useful addition to the diabetes treatment
arsenal, given their beneficial effects on CV risk
factors. Looking to the future, the results of
planned and ongoing trials to investigate
long-term safety and efficacy of SGLT2
inhibitors, especially in terms of CV outcomes,
will be of enormous interest. These results may
provide additional motivation for investigating
the use of SGLT2 inhibitors in the treatment of a
broader range of CV-related conditions.
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